| Literature DB >> 35904001 |
Emily A Siegrist1, Joseph Sassine2.
Abstract
Monkeypox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still cause significant morbidity and mortality. In this review, we explore three antiviral agents with activity against monkeypox and other orthopoxviruses: cidofovir, brincidofovir, and tecovirimat. Cidofovir, and its prodrug brincidofovir, are inhibitors of DNA replication with a broad spectrum of activity against multiple families of double-stranded DNA viruses. Tecovirimat has more specific activity against orthopoxviruses, and inhibits the formation of the extracellular enveloped virus necessary for cell-to-cell transmission. For each agent, we review basic pharmacology, data from animal models and reported experience in human patients.Entities:
Keywords: Monkeypox; brincidofovir; cidofovir; tecovirimat
Year: 2022 PMID: 35904001 DOI: 10.1093/cid/ciac622
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 20.999